These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 2808203

  • 1. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B, Naden M.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [Abstract] [Full Text] [Related]

  • 2. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ, Citron DM, Cherubin CE, Hillier SL.
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U, Manncke B, Gerbracht K, Werner H.
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [Abstract] [Full Text] [Related]

  • 4. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE, Lindmark A, Persson I.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
    Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
    [Abstract] [Full Text] [Related]

  • 6. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.
    Sheikh W, Pitkin DH, Nadler H.
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S361-6. PubMed ID: 8324148
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of L-627 against anaerobic bacteria.
    Nord CE, Lindmark A, Persson I.
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):757-60. PubMed ID: 1425740
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
    Appelbaum PC, Spangler SK, Jacobs MR.
    J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.
    Murray PR, Niles AC.
    Diagn Microbiol Infect Dis; 1990 Aug; 13(1):57-61. PubMed ID: 2331851
    [Abstract] [Full Text] [Related]

  • 10. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [Abstract] [Full Text] [Related]

  • 11. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of meropenem compared to nine other antimicrobial agents: importance of its stability when used in agar dilution systems.
    Mudaliar UA, Furyk NI, Moritz VA, Mayall BC.
    Pathology; 1996 Nov; 28(4):352-5. PubMed ID: 9007956
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM, Engel AE, Glass D, Li C.
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of imipenem against anaerobic bacteria.
    Wexler HM, Finegold SM.
    Rev Infect Dis; 1985 Oct; 7 Suppl 3():S417-25. PubMed ID: 3901206
    [Abstract] [Full Text] [Related]

  • 15. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML, Kempf M, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M.
    BMC Infect Dis; 2010 Mar 18; 10():72. PubMed ID: 20298555
    [Abstract] [Full Text] [Related]

  • 16. [Activity of doripenem against anaerobic bacteria].
    Dubreuil L, Neut C, Mahieux S, Muller-Serieys C, Jean-Pierre H, Marchandin H, Soussy CJ, Miara A.
    Pathol Biol (Paris); 2011 Apr 18; 59(2):102-7. PubMed ID: 20537808
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of imipenem against gram-positive anaerobic bacteria.
    Dubreuil L, Devos J, Romond C.
    Int J Clin Pharmacol Res; 1987 Apr 18; 7(1):39-43. PubMed ID: 3473047
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.
    Aldridge KE, Morice N, Schiro DD.
    Antimicrob Agents Chemother; 1994 Apr 18; 38(4):889-93. PubMed ID: 8031067
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial in vitro-activity of meropenem against 200 clinical isolates in comparison to 11 selected antibiotics.
    Lang C, Beuth J, Ko HL, Tunggal L, Pulverer G.
    Zentralbl Bakteriol; 1992 Dec 18; 277(4):485-92. PubMed ID: 1303691
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
    Hu J, Zhang J, Wu S, Zhu D, Huang H, Chen Y, Yang Y, Zhang Y.
    Int J Antimicrob Agents; 2014 Dec 18; 44(6):514-9. PubMed ID: 25301712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.